Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP000078

Drug Information
NameDihydroergotamine
SynonymsNCGC00017400-06; CHEMBL1732; Ergotaman-3',6',18-trione, 9,10-dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'alpha,10alpha)-; BRD-K72166146-066-02-1; Ergomimet; Orstanorm; Angionorm; Dihidroergotamina; IDI1_000592; Morena; Ergont; LS-64563; (10alphaH)-5'alpha-benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxo-9,10-dihydroergotaman; Co-Dergocrine; Spectrum3_000395; BRN 5720196; Ergoloid dihydroergotoxine; DET MS; Ergoloid Mesylates (dihydroergotoxine); DivK1c_000592; Diergo; SPBio_001235; CHEBI:4562; Agit; Dihydroergotoxin; Ambotz511-12-6; DIHYDROERGOTOXINE; 9,10-dihydro-ergotamine; KBio2_006673; Diidroergotamina; KBio2_004105; CID10531; dihydroergotamine; Ergotamine, 9,10-dihydro-; BSPBio_002209; Dihydroergotamine methanesulfonate; KBio2_001537; UNII-436O5HM03C; Dergotamine; DB00320; Verladyn; D.H.E.; 9,10-Dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)ergotoman-3',6',18-trione; KBioSS_001537; D07837; NINDS_000592; KBio1_000592; KBio3_001429; Ergotonin; LS-61979; Spectrum_001057; Ergot Alkaloids, Hydrogenated; Dihidroergotamina [INN-Spanish]; DHE-45; 9,10-Dihydroergotamine; Neomigran; 6190-39-2 (mesylate); Migranal; Dihydroergotaminum; Spectrum5_000905; CHEBI:658566; KBioGR_001576; Dihydroergotamine (INN); Tonopres; (5'alpha)-12'-Hydroxy-2'-methyl-5'-(phenylmethyl)ergotoman-3',6',18-trione; Dirgotarl; Spectrum4_000958; Dihydergot; Neomigran (TN); Diidroergotamina [DCIT]; C07798; Spectrum2_001188; (5'alpha)-5'-benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxoergotaman; Dehydroergotamine; EINECS 208-123-3; C33H37N5O5; Dihydroergotaminum [INN-Latin]; Seglor; Endophleban; Ergotoxine, dihydro-; Lopac0_000357; 5'-Benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxo-9,10-dihydroergotaman; AC1L1VEA; 511-12-6; Ikaran; BIDD:GT0120
Trade NameD.H.E. 45; Migranal
CompanyPfizer Pharmaceuticals
IndicationMigraine headaches
[ICD9: 346   ICD10: G43]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C33H37N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-3
4-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-
13-7-12-27(37)33(38,42)43-32/h3-6,8-11,17,21,23,25-27,34,42H,7,12
-16,18H2,1-2H3,(H,35,39)/t21-,23-,25-,26+,27+,32-,33+/m1/s1
InChIKeyLUZRJRNZXALNLM-JGRZULCMSA-N
Canonical SMILESCC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CC6C(CC7=CNC8=CC=
CC6=C78)N(C5)C    
Isomeric SMILESC[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@
H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C
Therapeutic ClassAnti-migraine Agents
CAS NumberCAS 6190-39-2
FormulaC33H37N5O5
PubChem Compound IDCID 10531.
PubChem Substance IDSID 10000.
SuperDrug ATC IDN02CA01
SuperDrug CAS ID000511126;
TargetAlpha adrenergic receptorAgonist[2]
Ref 1Migraine: a pharmacologic review with newer options and delivery modalities. Neurology. 1994 May;44(5 Suppl 3):S13-7. To Reference
Ref 2Current and prospective pharmacological targets in relation to antimigraine action. Naunyn Schmiedebergs Arch Pharmacol. 2008 Oct;378(4):371-94. Epub 2008 Jul 15. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543